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ABSTRACT 
Homozygous familial hypercholesterolaemia is a fatal disease if untreated and has a high 
prevalence of premature coronary artery disease. Ocular findings may help with earlier 
identification and coronary artery disease risk stratification. 
 
 
Objectives: The primary objective was to determine ocular findings in patients with 
homozygous familial hypercholesterolaemia. The secondary objective was to correlate 
ocular findings with clinical and biochemical data.  
 
 
Design and Method: A cross-sectional study was conducted in 2011. Thirty patients were 
recruited from the Lipid Clinic at Charlotte Maxeke Johannesburg Academic Hospital. 
 
  
Results: Xanthelasma palpebrarum, corneal arcus, retinal arteriosclerosis and visual field 
defects were detected. Xanthelasma palpebrarum and corneal arcus were common in 
patients with overt coronary artery disease. 
 
 
Conclusion: In addition to well-known ocular features of hyperlipidaemia, i.e. xanthelasma 
palpebrarum, corneal arcus and retinal arteriosclerosis, we detected visual field defects. The 
assessment of xanthelasma palpebrarum and corneal arcus may help to prognosticate 
coronary artery disease risk.  
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1. CHAPTER 1- INTRODUCTION 
 
1.1 GENERAL INTRODUCTION AND LITERATURE REVIEW  
Homozygous familial hypercholesterolaemia (HoFH) is a metabolic disorder with an 
autosomal co-dominant inheritance pattern.1  Mutations in genes coding for low-density 
lipoprotein receptors lead to elevated serum cholesterol levels.1  Homozygotes are severely 
affected with low-density lipoprotein cholesterol (LDL-C) levels approximately six times 
greater than the ideal level for patients at risk for heart disease.2 
  
 
The estimated prevalence of HoFH in South Africa is 1 in 30 000.3  In comparison, the global 
prevalence of HoFH is about 1 case per 1 million persons.4  The significant prevalence of 
HoFH in South Africa was a valuable resource to elucidate the ocular findings in these 
patients.  
 
 
Elevated LDL-C  levels  and decreased levels of high-density lipoprotein cholesterol (HDL-C) 
are known to be risk factors for coronary heart disease (CHD).5  According to the Centers for 
Disease Control and Prevention, ischaemic heart disease was the leading cause of death in 
the United States of America in 2014.6  The early detection and treatment of familial 
hypercholesterolaemia (FH) can ease the burden of CHD.   
 
 
The presence of elevated LDL-C levels may be inferred from the observation of lipid 
deposition in the eye which occurs in conditions such as corneal arcus and xanthelasma 
palpebrarum.  Arteriosclerosis of retinal vessels has been strongly correlated with the 
severity of atherosclerotic changes within coronary arteries.7  Therefore, ophthalmoscopy 
can be an invaluable, non-invasive, tool for clinicians to gauge systemic atherosclerosis from 
ocular findings.  
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Corneal arcus is a common, non-sight-threatening, ocular sign in hypercholesterolaemic 
patients.8  The width and circumference of corneal arcus have been associated with the 
extent and duration of elevated LDL-C levels.9  Corneal arcus has been associated with 
higher LDL-C levels, lower HDL-C levels and LDL-C: HDL-C ratio > 5.8  
 
 
Corneal arcus has also been proposed as a cardiac risk factor.9  Literature examining this 
association has yielded mixed results.  A study showed that corneal arcus was not a 
predictor of coronary artery disease (CAD) after the adjustment of age and gender.10  The 
majority of the patients with corneal arcus were graded as having slight corneal arcus.  In 
patients with severe corneal arcus, such as patients with HoFH, these findings may differ.  A 
correlation, however, between corneal arcus and severe calcific atherosclerosis was 
demonstrated in a small number of patients with HoFH.11   
 
 
Another, easily identifiable, ocular manifestation of hyperlipidaemia is xanthelasma 
palpebrarum which manifests as yellow plaque-like lesions near the inner canthus of the 
eye.12  Patients with xanthelasma palpebrarum may have an increased risk for CAD.12 
 
 
Hypercholesterolaemia has been linked to other ocular pathologies such as conjunctival 
xanthoma13, lens opacification14, retinal vein occlusion15 and age-related macular 
degeneration.16  Most of these diseases have the potential to severely affect vision and 
increase morbidity.  Atherosclerosis-related thrombosis is the most common cause of 
central retinal artery occlusion.17  Other findings associated with hypercholesterolaemia are 
changes in visual field testing18 and cholesterol emboli seen in retinal vasculature 
(Hollenhorst plaques)19.  
 
 
Visual field abnormalities in the absence of ophthalmological or neurological disease may 
indicate defective processing capabilities of the cerebral cortex due to hyperlipidaemia.18 
Perimetry values (mean deviation, pattern standard deviation, short-term fluctuation, 
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corrected pattern standard deviation and foveal threshold) measured in dyslipidaemic 
patients revealed a worsening of all perimetry variables.18 
  
 
1.2 RESEARCH AIM  
The aim was to describe pathological ocular findings in patients with HoFH. 
 
 
1.3  RESEARCH OBJECTIVES  
The primary objective was to investigate the spectrum of ocular findings in patients with 
HoFH. The secondary objective was to determine the association between ocular findings 
and clinical and biochemical data.  
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2. CHAPTER 2- METHODS 
 
2.1 STUDY DESIGN  
A cross-sectional study was conducted from the 05 April 2011 to the 19 July 2011. A 
convenience sample of 30 patients, attending the Lipid Clinic at Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH), was recruited to the study. They were examined 
after their routine follow up visit to the Lipid Clinic. 
 
   
2.2 DATA COLLECTION  
A research protocol was submitted to and reviewed by the Human Research Ethics 
Committee (Medical), University of the Witwatersrand. A clearance certificate was issued, 
Reference M110313 (Appendix A). The study commenced once approval was received.  
Permission was obtained from the Chief Executive Officer of CMJAH and the Head of the 
Division of Endocrinology & Metabolism at CMJAH, to review clinical records.   
 
 
The Lipid Clinic at CMJAH is one of the two main lipid clinics in the country, the other clinic 
being based at Groote Schuur Hospital. The drainage area of the clinic at CMJAH includes 
the whole of Gauteng and extends as far afield as Bloemfontein, Richards Bay and 
Harrismith. 
 
 
Thirty eligible participants were approached and invited to participate in the study. The 
sample size was limited by the number of subjects with this condition attending the Lipid 
Clinic at CMJAH. However, 30 is a large cohort for this rare condition.3 The period of the 
patients follow up visits determined the duration of the study. Patients and parents of 
paediatric patients were verbally informed about the study and the clinical examination. 
They were also provided with information sheets (Appendix B, Appendix C and Appendix D). 
Informed consent was obtained from patients (Appendix E) or parents/ legal guardians of 
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paediatric patients (Appendix F). An assent form (Appendix G) was signed by older 
paediatric participants when appropriate.   
 
 
Patients were examined at the eye clinic at CMJAH by the primary researcher. Visual field 
examination, ocular coherence tomography (OCT) images and colour fundus photographs 
were captured by Mrs Linda Malan. Corneal photographs were taken by the primary 
researcher. Professor I Mayet, a retinal expert, graded the colour fundus photographs. On 
the day of examination routine fasting lipid profiles were taken at the Lipid Clinic. Medical, 
surgical and biochemical data were collated from clinical records.  
 
 
2.2.1 Inclusion Criteria  
Adult and paediatric patients were invited to participate if they had HoFH. This was 
diagnosed by the following as noted in a review article by Raal and Santos.1 
a) Genetic testing detecting 2 mutated alleles at the low-density lipoprotein gene locus. 
b) Clinical diagnosis  
- Cutaneous or tendinous xanthomas occurring at a young age (<10 years) 
- Untreated LDL-C >13mmol/L 
- Treated LDL-C ≥7.76mmol/L 
- A non-HDL-C ≥8.5mmol/L 
c) Hypercholesterolaemia in both parents or CAD in a first degree relative (male < 55years 
and female < 60years) 
 
 
2.2.2 Exclusion Criteria 
Exclusion criteria were: 
 Diabetes mellitus. This was defined as fasting blood glucose of ≥7.0 mmol/l20, a patient 
with classic symptoms of hyperglycaemia or hyperglycaemic crisis and a random glucose 
level ≥11.1mmol/L20, self-reported diabetes or patients taking glucose lowering 
medication. Patients with diabetes mellitus were excluded because it has been linked to 
cataract formation, increased intraocular pressure (IOP) and retinal vein occlusion.  
   6 
 
 Hypertension. This was defined as a clinic blood pressure of 140/90 mmHg or higher and 
subsequent ambulatory blood pressure monitoring daytime average or home blood 
pressure monitoring average of 135/85 mmHg or higher21, self-reported hypertension or 
patients on therapy for hypertension. Hypertensive patients were excluded from the 
assessment of retinal arteriosclerosis because hypertension can also cause 
arteriosclerosis of the retinal arteries and is a risk factor for retinal vein occlusion. 
Hypertensive retinopathy closely resembles atherosclerotic disease of retinal arteries. 
Due to the small sample size, the 3 hypertensive patients were included in the 
evaluation of all other ocular signs but excluded from the retinal examination for 
arteriosclerosis.    
 History of eye trauma, or ocular inflammation because they can lead to cataract 
formation, increased IOP and visual field defects.  
 Corticosteroid usage as it may lead to increased IOP and cataract formation. 
 Current smokers and/or excessive alcohol intake i.e. >30g/day. These are also CAD risk 
factors which may confound the evaluation of hypercholesterolaemia as a CAD risk 
factor. Smoking is also a risk factor for age-related macular degeneration.  
 History of glaucoma, or IOP> 21mmHg, Cup to disc ratio > 0.3. Glaucoma leads to defects 
in visual field testing.  
 Refractive defects > 6 dioptres and neuro-ophthalmological diseases that can affect 
perimetry results. 
 Patients in which the posterior segment was not visible. 
 Previous eye surgery. Complications of eye surgery include increased IOP and cataract 
formation. Topical steroids are also used to treat patients postoperatively which can 
lead to IOP elevations and cataract formation as mentioned above. 
 
 
2.2.3 Data Collection   
Confidentiality was maintained regarding patients names, hospital numbers and clinical 
information obtained. Each patient was identified by a study number only. Only the primary 
researcher had access to the study number-patient identity key. All information was kept 
confidential. The Lipid Clinic provided the primary researcher with patients’ demographic 
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data, biochemical data, and past medical and surgical history on a Microsoft Excel spread 
sheet.  
 
 
The following information was extracted from the clinic record (Appendix H): 
a) Age  
b) Sex 
c) Race  
d) Afrikaner Descent 
Due to the founder effect described by Seftal et al, there is a high prevalence of 
Afrikaner descent among patients with HoFH.3 
e) Overt coronary artery disease:  
1. Coronary artery bypass graft 
2. Aortic valve replacement  
3. Percutaneous transluminal coronary angioplasty 
4. Aortic arch procedure 
5. Combination of any of the above procedures  
6. Myocardial infarction 
f) Other vascular surgery: 
1. Abdominal aortic surgery  
2. Carotid surgery  
3. Other vascular procedures  
g) Cutaneous or tendinous xanthomas in the first decade 
h) Cholesterol-year score 
This was calculated using the average yearly LDL-C level and the age of the patient.22 
i) Total cholesterol, LDL-C and HDL-C levels.   
 
 
There was provision on the data capture sheet for information regarding angina, heart 
failure, cerebrovascular accident and transient ischaemic attacks. However, given the small 
number of patients in these groups we decided to rather focus on overt CAD and other 
vascular surgery as the clinical characteristics that would be investigated.  
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The ocular examination was documented on a data capture sheet (Appendix H). It was 
performed by the primary researcher and took place at the ophthalmology clinic at CMJAH. 
Mrs Malan performed the 24-2 visual field test using a Humphreyᴿ 740i Field Analyzer (Carl 
Zeiss, Oberkochen, Germany). She also captured OCT images with a Stratus OCT machine 
(Carl Zeiss, Oberkochen, Germany) and colour fundus pictures with a TRC-50DX retinal 
camera (Topcon, Tokyo, Japan).  
 
 
Upon arrival visual acuity was tested using a Snellen chart. Thereafter visual fields were 
tested. Patients were then examined for the presence of xanthelasma palpebrarum, 
conjunctival xanthomas and corneal arcus using a SL990-Zoom slit lamp (CSO, Firenze, Italy). 
Corneal photographs of both eyes were taken by the primary examiner using a 3.15 
megapixel camera (Blackberry, Ontario, Canada), held approximately 15cm from the corneal 
surface, to document corneal arcus. IOP was measured using a Goldman applanation 
tonometer. 
 
 
Eyedrops containing cyclopentolate and phenylephrine were used for pupillary dilation. One 
drop was instilled in each eye. An additional drop was given after 10 and 20 minutes until 
there was adequate pupillary dilation. Slit lamp examination recommenced to assess for 
cataract formation. Direct ophthalmoscopy of the optic disc, macula and retinal vasculature 
was performed using a 78 dioptre lens (Ocular Instruments, Washington D.C, United States 
of America). Thereafter patients proceeded to have an OCT and colour fundus image 
captured. Retinal photographs were then sent to the retinal expert on a CD disc for grading.  
 
 
A circular overlay, designed using Microsoft PowerPoint 2010 (Microsoft, United States of 
America), with a radius larger than the corneoscleral junction was superimposed on corneal 
photographs (Figure 1).  The circle was divided into eight equal sectors.  A score of 1 was 
given for corneal arcus completely or half filling a sector. Each eye was scored from 0 (no 
arcus) – 8 (complete circumferential arcus).  The scores from both eyes were added and 
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divided by 16, producing a final grade ranging from 0 (no arcus bilaterally)-1 (complete 
circumferential arcus bilaterally).11  The grading of corneal arcus was performed by the 
primary researcher.  
 
 
 
Figure 1: Circular overlay over corneal pictures to grade corneal arcus 
 
 
Visual field tests were analysed by the primary researcher. Firstly, it was determined 
whether or not the visual field results were reliable. This assessed if the patient followed 
instructions on how to perform the test. The blind spot which correlates with the optic disc 
was tested to determine if the patient maintained fixation. If fixation losses were in excess 
of 20% the test was deemed to be of poor reliability23 and not analysed. Secondly, if false 
positive or false negative scores were >20-30%, the test was noted to be of questionable 
reliability and not further interpreted.23 One of the numerical indices on the visual field test 
is the mean deviation. It is a measure of the global deviation from normal values.23 Once a 
test was found to be reliable, the mean deviation was then assessed.  A mean deviation <-
2db is considered abnormal.23  
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Colour fundus photographs were only taken on 2 days over which 25 patients were 
examined. Unfortunately colour fundus photographs could only be captured in 17 patients 
as a result of poor patient co-operation (2 paediatric patients and the lengthy examination 
process) or malfunctioning of the retinal camera.  One hypertensive patient was excluded 
from the retinal arteriosclerosis examination. The other 16 patients were assessed for 
retinal arteriosclerosis by a retinal expert, Professor I. Mayet. The primary researcher also 
examined all fundi for retinal arteriosclerosis. This was done as the primary researcher was 
aware of demographic and clinical data and may have been biased. Additionally, the subtle 
change in Grade 1 arteriosclerosis is challenging to detect. This is a crucial finding as it 
determines the presence or absence of disease. This grading was therefore carried out by a 
retinal expert. The photographs were labelled with a number and the laterality of the eye. 
He was blind to the patients’ demographic and clinical data. The Scheie classification was 
used to grade retinal arteriosclerosis. 
 
 
Table 1: Scheie classification21 
Stage   
0 No abnormality. 
1 Widening of arteriole light reflex. 
Absent or  minimal  arteriolovenous 
compression. 
2 More noticeable light reflex and crossing 
changes. 
3 Copper wire appearance of arterioles. 
More arteriolovenous compression. 
4 Silver wire appearance of arterioles. 
Most severe arteriolovenous crossing 
changes. 
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2.3 STATISTICAL ANALYSIS  
The primary researcher performed the statistical analysis using Microsoft Excel version 14 
(Microsoft, United States of America) and Statistica version 12 (Soft Inc., United States of 
America).  Mr Nimalin Moodley and Mr Deepak Soowamber offered assistance with 
statistical queries. Microsoft Excel was used to compute the descriptive statistics of 
demographic variables and ocular findings. Continuous variables were described using 
means and standard deviations for normally distributed data and medians and interquartile 
ranges (IQR) for non-normally distributed data. Categorical data was described using 
percentages. When comparing categorical and numerical variables, if normally distributed, a 
t-test was performed. The Kruskal-Wallis test was used if normality was not met. When 
comparing categorical variables with categorical variables, the chi squared test was 
performed. A linear regression analysis was performed to determine the significance 
between corneal arcus grade and selected clinical characteristics. Those relationships found 
to be statistically significant were then adjusted for age and gender using a multiple 
regression analysis.  A linear regression analysis was also used to evaluate the relationship 
between retinal arteriosclerosis grade and selected clinical characteristics. Statistical 
significance was defined as a p value <0.05.   
 
 
2.4 STAFF AND ADMINISTRATION  
Professor F.J. Raal took the fasting blood samples at the Lipid Clinic on the day of 
examination. The ocular examination and corneal photographs were done by Dr Adisha 
Goberdhan (Ophthalmology registrar) at the CMJAH eye clinic. Mrs Linda Malan performed 
the visual field examinations and captured the OCT images and retinal photographs. 
Professor I. Mayet graded retinal arteriosclerosis by assessing the colour fundus 
photographs.  The primary researcher interpreted the visual field tests and OCT images.  
 
   
2.5 ETHICAL CONSIDERATIONS  
Approval for the study was obtained from the Human Research Ethics Committee, 
University of the Witwatersrand (Appendix A). Confidentiality was maintained regarding 
patients names, hospital numbers and clinical information obtained. 
   12 
 
3. CHAPTER 3- RESULTS 
 
3.1 STUDY SAMPLE 
A convenience sample of 30 patients was obtained from the Lipid Clinic (Table 2). 
   
 
Table 2: Demographics and clinical characteristics of the sample population 
Demographics  
Age (years)  24 (13- 38) 
Sex  
    Male 
    Female 
 
15 (50%) 
15 (50%) 
Race 
    White 
    Indian 
 
24 (80%) 
6 (20%) 
Afrikaner Descent 22 (73%) 
Clinical characteristics 
Overt CAD 10 (33%) 
Other vascular 
surgery 
2 (7%) 
Cholesterol-year 
score (mmol-year/L) 
281.16 (161.4- 509.1) 
Total Cholesterol 
(mmol/L) 
11.9± 3.6 
LDL-C (mmol/L) 10.4 ± 3.5 
HDL-C (mmol/L) 1.0 (0.8- 1.2) 
 
  
   13 
 
3.1.1 Age 
The youngest patient was 6 years old and the oldest was 49 years old. Fourteen patients 
were younger than 18 years of age. 
 
3.2 OCULAR FINDINGS  
3.2.1 Xanthelasma palpebrarum  
Xanthelasma palpebrarum was found in nine (30%) patients. There were four unilateral and 
five bilateral cases.  In unilateral cases, it predominantly (75%) occurred on the right eyelid.   
 
 
Table 3: Xanthelasma palpebrarum occurring in the right and left eye in unilateral and 
bilateral cases   
Xanthelasma palpebrarum Right eye (n=8) Left eye (n=6) 
Unilateral (n=4) 3  1 
Bilateral (n=5) 5 5 
 
 
Table 4: Location of the xanthelasma palpebrarum in each eye 
Xanthelasma palpebrarum Right eye (n=8) Left eye (n=6) 
Upper eyelid only 2 (25%) 1 (17%) 
Lower eyelid only 2 (25%) 2 (33%) 
Upper and lower eyelid 3 (38%) 3 (50%) 
Inner canthus 1 (13%) 0 
 
 
Xanthelasma palpebrarum was located more commonly on the upper and lower eyelids 
(Table 4). 
 
 
 
   14 
 
Table 5: Demographic and clinical characteristics of patients with and without 
xanthelasma palpebrarum 
 Xanthelasma 
palpebrarum 
(n=9) 
No Xanthelasma 
palpebrarum 
(n=21) 
p-value 
Age (years) 34 (30- 43) 17 (12- 36) 0.049 
Males 7 (78%) 8 (38%) 0.046 
Females 2 (22%) 13 (62%) 0.046 
Race 
     White 
     Indian 
 
7 (78%) 
2 (22%) 
 
17 (81%) 
4 (19%) 
 
0.842 
0.842 
Afrikaner descent  6 (67%) 16 (76%) 0.589 
Overt CAD 6 (67%) 4 (19%) 0.011 
Other vascular 
surgery 
 
0 (0%) 2 (10%) 0.338 
Cholesterol-year 
score (mmol-
year/L) 
448.6 (281.5- 538.5) 234.8 (131.0- 450.7) 0.067 
Total cholesterol 
(mmol/L) 
11.7± 4.0 12.0± 3.6 0.807 
LDL-C (mmol/L) 10.1± 3.9 10.5± 3.5 0.763 
HDL-C (mmol/L) 1.0 (0.7- 1.2)  1.0 (0.9 - 1.1)  0.584 
 
 
Xanthelasma palpebrarum was more common in older patients, men and those with overt 
CAD (Table 3).  
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Table 6: Age of patients with xanthelasma palpebrarum vs age of male patients with 
xanthelasma palpebrarum 
Age of patients with 
xanthelasma palpebrarum 
Age of male patients with 
xanthelasma palpebrarum 
p- value 
34 (30- 43) 32 (23- 46) 0.916 
 
 
Table 7: Age of patients with xanthelasma palpebrarum vs age of xanthelasma 
palpebrarum patients with Overt CAD 
Age of patients with 
xanthelasma palpebrarum 
Age of xanthelasma 
palpebrarum patients with 
Overt CAD 
p- value 
34 (30- 43) 40 (35- 47) 0.289 
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Table 8:  Demographic and clinical characteristics of patients with unilateral and bilateral 
xanthelasma palpebrarum 
  Unilateral 
Xanthelasma 
palpebrarum 
(n= 4) 
Bilateral 
Xanthelasma 
palpebrarum 
(n= 5) 
p-value 
Age (years) 23 (14- 31) 43 (36- 48) 0.014 
Males 4 (100%) 3 (60%) 0.151 
Females 0 (0%) 2 (40%) 0.151 
Race 
     White 
     Indian 
 
2 (50%) 
2 (50%) 
 
5 (100%) 
0 
 
0.073 
0.073 
Afrikaner descent  1 (25%) 5 (100%) 0.018 
Overt CAD 1 (25%) 5 (100%) 0.018 
Other vascular 
surgery 
0 0 N/A 
 
Cholesterol-year 
score (mmol-
year/L) 
244.1 (204.9- 293.6) 538.5 (532.8- 538.8) 0.014 
Total cholesterol 
(mmol/L) 
9.4± 3.1 13.5± 3.8 0.126 
LDL-C (mmol/L) 8.0± 3.2 11.8.4± 3.8 0.160 
HDL-C (mmol/L) 0.9 (0.7- 1.2) 1.0 (0.9- 1.2) 0.712 
 
 
3.2.2 Conjunctival Xanthomata 
Conjunctival xanthomata were not detected in any patient.  
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3.2.3 Corneal Arcus 
Of the 30 patients, 29 were assessed for corneal arcus. Two patients were excluded from 
the assessment of corneal arcus due to poor quality images.  
 
 
Table 9: Demographic and clinical characteristics of patients with and without corneal 
arcus 
 Corneal arcus 
(n= 22) 
No corneal arcus 
(n= 6) 
p-value 
Age (years) 33 (15- 41) 13 (12- 16) 
 
0.016 
Males 12 (55%) 
 
1 0.099 
Females 10 (45%) 5 0.099 
Race 
     White 
     Indian 
 
18 (82%) 
4 (18%) 
 
5 (83%) 
1 (17%) 
 
0.932 
0.932 
Afrikaner descent  16 (73%) 5 (83%) 0.595 
Overt CAD 10 (45%) 0 0.039 
Other vascular 
surgery 
2 (9%) 0 0.443 
Cholesterol-year 
score (mmol-year/L) 
402.5 (218.3- 532.8) 155.2 (121.8- 250.9) 0.016 
Total cholesterol 
(mmol/L) 
11.6± 3.7 11.9± 3.2 0.855 
LDL-C (mmol/L) 10.0± 3.7 10.4± 2.9 0.828 
HDL-C (mmol/L) 1.0 (0.8- 1.2) 1.1 (0.9-1.1) 0.538 
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Patients with corneal arcus were significantly older and had higher cholesterol-year scores 
compared with those without corneal arcus. Importantly, overt CAD was more common in 
those with corneal arcus (Table 7).  
 
 
A 15 year old female, non-Afrikaner, Caucasian patient had unilateral corneal arcus. She did 
not have any history of overt CAD or other vascular surgery. Her cholesterol-year score was 
234.8mmol-year/L, total cholesterol was 4.8mmol/L, LDL-C was 3.3mmol/L and HDL-C was 
1.2mmol/L. The corneal photograph was of a poor quality to accurately grade the degree of 
corneal arcus. Twenty one patients had bilateral corneal arcus. The median age was 34 with 
an IQR of 17-42. Twelve patients (57%) were male. The majority were White (81%) and of 
Afrikaner descent (76%). Ten patients (48%) had overt CAD and 2 (10%) had other vascular 
surgery. The median cholesterol-year score was 448.6mmol-year/L with an IQR of 
218.3mmol-year/L - 532.8mmol-year/L. The mean total cholesterol was 11.9mmol/L and the 
mean LDL-C was 11mmol/L. The median HDL-C was 1.0mmol/L with an IQR of 0.8mmol/L- 
1.2mmol/L. 
  
 
Figure 2: Corneal arcus grade in patients with corneal arcus 
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Table 10: Unadjusted relationship between corneal arcus grade and selected clinical 
characteristics 
 Regression coefficient  p-value 
Age  0.445 0.018 
Overt CAD 0.389 0.041 
Other vascular surgery 0.042 0.830 
Cholesterol-year score 0.493 0.008 
Total cholesterol 0.192 0.327 
LDL-C 0.174 0.378 
HDL-C 0.167 0.410 
 
 
In unadjusted analyses, there was a significant relationship between corneal arcus grade 
and age, overt CAD and cholesterol-year score. All of these relationships were attenuated by 
adjustment for age and gender. 
 
 
3.2.4 Cataracts  
Cataract formation was not detected in 29 patients. Assessment of cataract formation was 
incomplete in one patient who declined dilation. 
 
  
3.2.5 Intraocular pressure 
IOP was measured in 22 patients. Of the eight patients without documented IOPs, six were 
paediatric patients in whom IOP examination was deferred and two patients IOPs were not 
documented possibly due to patient discomfort.  All pressures taken were within normal 
range. The median pressure in the right and left eye was 11.5mmHg and 11.0mmHg 
respectively.  
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3.2.6 Retinal Arteriosclerosis  
Seventeen patients had fundus photography, but 16 were assessed as one was excluded due 
to hypertension. 
 
 
Table 11: Demographic and clinical characteristics of patients with and without retinal 
arteriosclerosis 
 Retinal 
arteriosclerosis 
(n= 9) 
No Retinal 
arteriosclerosis 
(n= 7) 
p-value 
Age (years) 31 (22- 36) 13 (6- 17) 0.013 
Males 4 (44%) 3 (43%) 0.949 
Females 5 (56%) 4 (57%) 0.949 
Race 
     White 
     Indian 
 
7 (78%) 
2 (22%) 
 
4 (57%) 
3 (43%) 
 
0.377 
0.377 
Afrikaner descent  7 (78%) 4 (57%) 0.377 
Overt CAD 4 (44%) 1 (14%) 0.197 
Other vascular 
surgery 
0 0 N/A 
Cholesterol-year 
score (mmol-year/L) 
356.5 (218.3- 475.4) 149.0 (104.0- 280.8) 0.010 
Total cholesterol 
(mmol/L) 
12.1± 3.4 12.0± 2.8 0.946 
LDL-C (mmol/L) 10.6± 3.3 10.5± 2.6 0.972 
HDL-C (mmol/L) 0.9 
(0.8- 1.4) 
1.0 (0.9 - 1.1) 0.831 
 
 
Patients with retinal arteriosclerosis were significantly older and had higher cholesterol-year 
scores than those without retinal arteriosclerosis. (Table 10) 
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Figure 3: Colour fundus picture of the right eye in a patient with grade two retinal 
arteriosclerosis 
 
 
All patients with retinal arteriosclerosis had bilateral disease. Of the 9 patients with retinal 
arteriosclerosis, 4 (44%) had overt CAD. The maximum grade of retinal arteriosclerosis in 
patients with overt CAD was 2 compared to patients without overt CAD who had a 
maximum grade of 3. 
 
 
 
Figure 4: The retinal arteriosclerosis grade of patients with retinal arteriosclerosis 
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Table 12: Relationship between the maximum retinal arteriosclerosis grade and selected 
clinical characteristics 
 Regression 
coefficient  
p-value 
Age -0.388 0.302 
Overt CAD -0.254 0.51 
Cholesterol-year score -0.371 0.33 
Total cholesterol 0.057 0.89 
LDL-C 0.091 0.82 
HDL-C -0.447 0.23 
 
 
The lack of colour fundus photographs in patients with other vascular surgery prevented the 
assessment of retinal arteriosclerosis. No significant relationships were found between the 
retinal arteriosclerosis grade and the above selected clinical characteristics. 
 
3.2.7 Ocular Coherence Tomography 
OCT images were captured on 22 patients. Eight of these patients were <18 years of age. 
The youngest patient was 6 years old and the oldest was 49 years old. Of the 8 patients in 
whom OCT images were not obtained, 4 patients were <18 years old.  
 
 
3.2.8 Retinal Vein Occlusion 
There was no evidence on clinical examination and OCT of present or previous episodes of 
retinal vein occlusion.  
 
 
3.2.9 Retinal Artery Occlusion 
There was no evidence of present or previous episodes of retinal artery occlusion in either 
eye in any patient.  
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3.2.10 Age-Related Macular Degeneration 
Neither dry nor wet ARMD was detected in any eye on clinical examination and OCT (Figure 
5).  
 
 
 
Figure 5: Normal OCT image 
 
 
3.2.11 Hollenhorst Plaques  
Hollenhorst plaques were not found in any patient.  
 
 
3.2.12 Visual fields 
Visual field testing was performed bilaterally in 23 patients. Nineteen patients had reliable 
visual fields either unilaterally or bilaterally. Five paediatric patients were not offered this 
test because of the level of understanding and concentration required to perform it reliably. 
Two adult patients refused testing.  
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Table 13: Demographic and clinical characteristics of patients with and without abnormal 
mean deviations on reliable visual field tests 
 Unilateral/ bilateral 
reliable visual 
field/fields with 
abnormal mean 
deviation  
(n= 7) 
Unilateral/ bilateral 
reliable visual field/ 
fields without 
abnormal mean 
deviation  
(n= 12) 
p-value  
Age (years) 13 (8- 42) 31 (19- 39) 0.237 
Males 3 (43%) 7 (58%) 0.515 
Females 4 (57%) 5 (42%) 0.515 
Race 
     White 
     Indian 
 
5 (71%) 
2 (29%) 
 
9 (75%) 
3 (25%) 
 
 
0.865 
0.865 
Afrikaner descent  5 (71%) 9 (75%) 0.865 
Overt CAD 1 (14%) 5 (42%) 0.216 
Other vascular 
surgery 
1 (14%) 5 (42%) 0.433 
Cholesterol-year 
score (mmol-year/L) 
206.7 (131.0- 450.7) 331.2 (262.0- 535.8) 0.052 
Total cholesterol 
(mmol/L) 
10.9± 3.7 12.4± 3.3 0.266 
LDL-C (mmol/L) 9.5± 3.7 10.9± 3.2 0.301 
HDL-C (mmol/L) 1.1 
(0.8 - 1.1) 
1.0  
(0.8 - 1.3) 
0.931 
 
 
Of the 23 patients tested, 5 (22%) had a reliable right eye visual field test with an abnormal 
mean deviation and 5 (22%) had a reliable left eye visual field test with an abnormal mean 
deviation. 
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Table 14: Median and IQR of unilateral and bilateral abnormal mean deviations in each 
eye 
 Median (IQR) 
Right eye Abnormal Mean Deviation (n= 5) -2.3 (-6.2- -2.2) 
Left eye Abnormal Mean Deviation MD (n= 5) -5.4 (-5.7- -4.4) 
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4. CHAPTER 4- DISCUSSION AND CONCLUSION 
 
This study primarily sought to determine the ocular features in patients with homozygous 
familial hypercholesterolaemia attending the Lipid Clinic at CMJAH. Xanthelasma 
palpebrarum, corneal arcus, retinal arteriosclerosis and visual field defects were detected. 
Conjunctival xanthomata, cataracts, retinal vein occlusions, retinal artery occlusions, age-
related macular degeneration and Hollenhorst plaques were absent. The majority of 
patients were Caucasian and of Afrikaner descent. This is in keeping with the founder effect 
elucidated by Seftal et al.3   
 
 
Xanthelasma palpebrarum is commonly found on the upper lid.24  However, in our study, it 
was found to occur more commonly on the upper and lower eyelids simultaneously. A male 
predominance was also noted. This differs from the lack of sex predilection noted in the 
literature.25  The majority of unilateral cases were found to be right sided. Unilateral carotid 
plaques were found to be twice as common on the left rather than on the right (p<0.001) in 
a large population based cohort, The Rotterdam Study.26 The characteristics of carotid 
atherosclerotic plaque deposition was analysed using MRI imaging.26 It would be of 
diagnostic value in our patients to determine whether laterality of xanthelasma 
palpebrarum correlates with carotid atherosclerotic deposition.   
 
 
Xanthelasma palpebrarum was more common in older patients, men and those with overt 
CAD. Subanalyses examining the distribution of age in patients with xanthelasma 
palpebrabum and the distribution of age of the male xanthelasma palpebrabum patients as 
well as those with overt CAD showed that there was no significant different between these 
groups. Therefore, even though xanthelasma palpebrarum was more prevalent in males and 
those with overt CAD, age could be a confounding factor.  
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The pathogenesis of xanthelasma palpebrarum seems to resemble the formation of 
atherosclerotic plaques.24 This has stimulated research to determine whether xanthelasma 
can serve as a predictor of cardiovascular disease.25,27  A large Danish prospective study by 
Christoffersen et al showed that xanthelasma palpebrarum was able to determine the risk of 
ischaemic heart disease, severe atherosclerosis, myocardial infarction and death in the 
general population.25 It was carried out from 1976/1978 up until May 2009. Being part of 
the Copenhagan City Heart Study, 12745 people were included in the study and 563 
participants had xanthelasma palpebrarum at the initial examination. There was a 100% 
follow up. The diagnosis of myocardial infarction and ischaemic heart disease were 
determined and confirmed by analysing the national Danish Patient Registry for all hospital 
admissions,  the national Danish Causes of Death Registry and evaluating hospital and 
general practioner records.25  
 
 
Ozdol et al performed a case-control study between January 2002 and October 2004.27 One 
hundred patients with xanthelasma palpebrarum were compared with 100 age and sex 
matched patients. The cardiovascular risk factors were comparable between the groups 
except that the patients with xanthelasma palpebrarum had a higher prevalence of 
hyperlipidaemia. Clinically  overt cardiovascular disease was similar between the groups. 
History and a resting ECG were used to determine the presence of cardiovascular disease. 
This could have lead to underdiagnosis in asymptomatic patients with cardiovascular 
disease who did not perform strenous daily activities or those with silent ischaemia. The use 
of a resting ECG for diagnosis may have missed patients with significant CAD or angina.27  
 
 
We found that overt CAD was more common in those with xanthelasma palpebrarum  
(p= 0.011) . Xanthelasma palpebrarum is a grossly detectable sign that can be easily 
detected by a clinician and does not necessarily require an ophthalmologist to assist with 
diagnosis. Therefore its ability to identify patients at risk for CAD can help to reduce the 
cardiovascular morbidity and mortality associated with HoFH. We also found that all 
patients with bilateral xanthelasma palpebrarum had overt CAD (p= 0.018). This can be an 
additional factor for determining patients at risk for CAD.  
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Corneal arcus is a known peripheral corneal opacity associated with hypercholesterolaemia. 
A review article by Fernández et al credits Virchow as the first person to suggest that 
corneal arcus was a cardiac risk factor.9 However, this relationship has remained 
controversial.9,10 A large prospective study used the Framingham Heart Study Original 
Cohort and Offspring database.10 Of the 23376 people examined, 3890 had corneal arcus. 
Corneal arcus was found to be a predictor for cardiovascular and CHD. But this relationship 
was not sustained after an adjustment for age and gender. Corneal arcus was only 
diagnosed and graded on visual inspection without the use of a slit lamp. This may have 
contributed to under-diagnosis.10  
 
 
A study of 17 homozygous familial hypercholesterolaemic patients by Zech and Hoeg found 
that the presence of corneal arcus correlated with the existence of calcific atherosclerosis.11 
The number of patients with corneal arcus (n=9) was small. We used their grading system to 
quantify the extent of corneal arcus in our study.  They noted that patients with more 
extensive corneal arcus had more severe atherosclerosis.11 We found that overt CAD was 
more common in those with corneal arcus. Therefore the presence of corneal arcus may be 
a marker for CAD. The statistically significant relationship between the grade of corneal 
arcus and overt CAD was not maintained after adjustment for age and gender.  
 
 
The prevalence of corneal arcus in dyslipidaemic patients has been shown to strongly 
correlate with risk factors implicated in the development of various circulatory diseases.8  A 
study by Meyer et al,  of 115 dyslipidaemic patients, revealed significantly higher levels of 
LDL-C, higher LDL-C: HDL-C ratios and lower levels of HDL-C in the subgroup of patients with 
corneal arcus.8 In comparison to our study there were a larger number of patients with 
corneal arcus (n=43) and all patients were treatment naïve.8 Our study revealed a slightly 
lower mean LDL-C level (p= 0.828) and total cholesterol level (p= 0.856) in those with 
corneal arcus. The median HDL-C levels (p= 0.535) were the same in patients with and 
without corneal arcus. We additionally used the cholesterol-year score as a clinical variable 
which was more than two times greater in patients with corneal arcus (p=0.016). The 
cholesterol-year score may have proved to be a more valuable predictor because it 
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correlates with the patients’ lifetime exposure to elevated cholesterol levels whereas other 
lipid parameters are merely a reflection of the patients’ cholesterol at a single point in time.  
The relationship between the corneal arcus grade and the cholesterol-year score was not 
statistically significant after adjustment for age and gender.  
 
 
The gold standard for diagnosing CAD is coronary angiography. This intensive procedure is 
not indicated for patients considered at early risk for CAD.28 Retinal microvasculature can be 
viewed much more easily. This has fueled research into finding correlations between retinal 
vessel abnormalities and CHD in the hope of easily identifying and stratifying patients with 
CHD.28, 29 Our colour fundus photographs were graded by a retinal specialist. We found no 
significant relationship between the presence or grade of retinal arteriosclerosis and CAD. 
However, the grading of retinal vasculature in an Australian population based study, The 
Blue Mountains Eye Study, revealed that a reduced arteriolar calibre and reduced arteriole 
to venule ratio (AVR)  was associated with a greater risk of CHD related death in women 
only.30 A larger venule calibre was associated with a greater risk of CHD related death in 
both sexes.30 Their study was strengthened by the use of a computer based program to 
determine the calibre of vessels and the AVR.30 This objective measure of the retinal 
vasculature and the examination of additional parameters such as venule calibre and AVR 
can be used in future studies to help elucidate this relationship in our study sample. A larger 
population based study in the United States of America, The Atherosclerosis Risk in 
Communities Study, found that retinal arteriolar and venular calibres correlated with CHD in 
women.31 The postulation that microvascular disease is more severe in women thus garners 
momentum.30 Of note, the additional use of retinal vessel calibre to determine the 
atherosclerotic cardiovascular disease event risk changed 21% of women from a low risk 
category to an intermediate risk category.31 This has substantial clinical implications and 
thus provides impetus to delve further into this relationship.   
 
 
We noted abnormalities in mean deviation on visual field testing in some patients. There 
were no associated abnormal IOPs or glaucomatous changes of the optic nerve head. 
Therefore, these changes may be suggestive of abnormalities in the cortical processing of 
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visual stimuli in hypercholesterolaemic patients.18  A wide range of statistically significant 
visual field abnormalities (mean deviation, pattern standard deviation, short-term 
fluctuation, corrected pattern standard deviation and foveal threshold)  were detected in a 
case control study, on treatment naïve patients, conducted by Alcalá et al.18 Our patients 
were not treatment naïve and statin usage has proved beneficial in improving visual field 
defects due to hypercholesterolemia.32  The study by Alcalá et al consisted of a larger study 
population and patients performed visual field tests twice to improve the reliability of the 
test.18  Based on our study, further research is required to assess other perimetry values.  
The reproducibility and progression of found defects also needs to be evaluated on 
repeated visual field testing.  
 
 
The major confounder in our study was that all patients were on statin therapy. Statins have 
been noted to increase the velocity and flow in retinal arteries and veins33, significantly 
decrease IOP33 , decrease the risk of cataract formation34 and have protective effects in age-
related macular degeneration35. The major limitation of the study was the small sample size. 
This was accounted for by the rarity of the disease3. Pooling data from the other Lipid Clinic 
based at Groote Schuur Hospital may improve the statistical power of future studies. A 
weakness of the study was that there was no masking in the grading of corneal arcus 
photographs, interpretation of visual fields and interpretation of OCT images as it was done 
by the primary investigator. However, retinal arteriosclerosis was graded by a retinal expert 
who was unaware of the patient’s medical history and clinical examination.     
 
 
In conclusion, ischaemic heart disease is a leading cause of death6 and thus remains a focus 
for ongoing research. The prevalence of HoFH in South Africa afforded us the unique 
opportunity of studying the ocular features in this rare subset of patients. Our patients, all 
of which were <50 years of age, displayed well-known ocular features of hyperlipidaemia 
such as xanthelasma palpebrarum, corneal arcus and retinal arteriosclerosis. In addition, we 
detected visual field defects. Xanthelasma palpebrarum, particularly when bilateral, and 
corneal arcus were common in patients prevalent with overt CAD. These non-invasive 
clinical signs may prove to be an invaluable tool in reducing the burden of CAD.  
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6. APPENDIX A: ETHICS CLEARANCE CERTIFICATE 
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7. APPENDIX B: INFORMATION SHEET FOR PATIENTS ATTENDING THE LIPID 
CLINIC AT CMJAH  
Dear Patient 
 
 
My name is Dr Adisha. I am currently training to be an eye specialist. I am doing a study to 
find out what eye changes are associated with high cholesterol levels. High cholesterol levels 
can cause changes to the eye. This study will help doctors know which changes to look for in 
patients with high cholesterol levels. It will also allow health workers to identify signs that 
may be associated with increased cholesterol levels so that the disease can be picked up 
earlier and treatment can be started. 
 
 
The study will be performed at the Johannesburg Hospital. The examination will be as 
follows: 
 You will read letters off a chart that is placed at a distance. This allows us to assess 
how well you can see. 
 I will perform a routine eye examination looking at the different parts of the eye.  
 The pressure within the eye will be measured. This will not be painful. 
 Your pupil (central black part of the eye) will be enlarged with the use of eye drops so 
that the back of the eye can be adequately seen. We recommend that you should not 
drive or engage in hazardous activities when your pupil is dilated. Transport will be 
arranged for your convenience.  
 Colour pictures and photographs of the eye will be taken. 
 A test will be done to assess your field of vision.  
 
 
Taking part in the study is voluntary (your choice). Your management will not be affected if 
you choose not to be part of the study. If your decision to participate changes, you are free to 
leave the study at any time. The results of this study are intended to be presented at a 
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conference and to be published. Your identity, examination findings and blood results will 
remain confidential.  
 
 
If you have any questions or concerns, please contact me, Dr Adisha Goberdhan, on 
0787573050. 
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8. APPENDIX C: INFORMATION SHEET FOR PARENTS/ LEGAL GUARDIANS 
OF CHILDREN ATTENDING THE LIPID CLINIC AT CMJAH 
 
Dear Parent/ Legal Guardian 
 
 
My name is Dr Adisha. I am currently training to be an eye specialist. I am doing a study to 
find out what eye changes are associated with high cholesterol levels. I would like to invite 
your child to be part of this study. 
 
 
High cholesterol levels can cause changes to parts of the eye. This study will help doctors 
know which changes to look for in patients with high cholesterol levels. It will also allow 
health workers to identify signs that may be associated with increased cholesterol levels so 
that the disease can be picked up earlier and treatment can be started. 
 
 
The study will be performed at the Johannesburg Hospital. The following examination will be 
performed:  
 Your child will read letters off a chart that is placed at a distance. This allows us to 
assess how well he/she can see. 
 I will perform a routine eye examination looking at the different parts of the eye.  
 The pressure within the eye will be measured. This will not be painful. 
 Your child’s pupil (central black part of the eye) will be enlarged with the use of eye 
drops so that the back of the eye can be adequately seen. We recommend that your 
child should not be involved in dangerous activities when their pupil is dilated.  
 Colour pictures and photographs of the eye will be taken. 
 A test will be done to assess their field of vision.  
 
You are free to choose whether or not you would like your child to participate in this study. 
The management of your child will not be affected if you decide that he/she should not be 
   38 
 
part of this study. You are free to remove your child from the study at any time. The 
examinations required to carry out this study are once off and a follow up visit is not 
necessary. However, your child will be followed up at the eye clinic if any abnormality that is 
found requires monitoring and/or investigation. The results of this study are intended to be 
presented at a conference and to be published. Your child’s identity, examination findings 
and blood results will remain confidential.  
 
 
If you have any questions or concerns, please contact me, Dr Adisha Goberdhan, on 
0787573050. 
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9. APPENDIX D: INFORMATION SHEET FOR CHILDREN ATTENDING THE 
LIPID CLINIC 
 
Hello, my name is Dr Adisha. I am training to become an eye specialist. I am studying 
patients who have high cholesterol levels to learn more about how cholesterol affects the eye. 
I would like you to be part of my study.   
 
 
The study will be performed at the Johannesburg Hospital. The following examination will be 
performed:  
 You will read letters off a chart. This tells us how well you can see. 
 I will look at the different parts of your eyes in detail. During this examination you 
will be seated. I will need you to sit still and look straight ahead. 
 The pressure within your eye will be measured. This will not be painful. 
 Eye drops will be used to make your pupil (round, black part in the centre of the eye) 
bigger so that the eye can be properly examined. Your eye sight will be blurry when 
your pupil is enlarged.  
 Colour pictures and photographs of your eye will be taken. 
 A test may be done to assess how well you can see lights coming from the side while 
looking ahead. 
 
 
The study has been discussed with your parent/ legal guardian. They have decided to allow 
you to participate in this study. However, you can still choose whether or not you would like 
to be part of the study. Your treatment will not be affected if you choose not to be part of the 
study. All information will be kept confidential.  
 
 
If you have any questions or concerns, please feel free to contact me on 0787573050.  
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10. APPENDIX E: CONSENT FORM FOR PATIENTS 
 
I, _________________________________________________________ 
hereby agree to be a part of this study. I have read and understood the information sheet 
provided to me. I am aware that participation in this study is voluntary and that I can leave 
this study at any time. 
 
 
_________________________               ___________________              __________ 
Name                                                        Signature                          Date 
 
 
__________________________                __________________            ___________ 
Doctors Name                                           Signature                                    Date 
 
 
__________________________                __________________            ___________ 
Witness                                                       Signature                                   Date 
 
  
   41 
 
11. APPENDIX F: CONSENT FOR PARENTS/ LEGAL GUARDIANS  
 
I, _________________________________________________________ 
hereby agree that my child, 
___________________________________________________________ 
can be a part of this study. I have read and understood the information sheet provided. I 
understand that participation in this study is voluntary and that my child can leave this study 
at any time. 
 
_________________________               ____________________          __________ 
Name of parent/ legal guardian                    Signature                                         Date 
 
  
________________________               ____________________           __________ 
Name of study doctor                             Signature                                         Date 
 
 
_________________________               ____________________          __________       
Witness                                                    Signature                                         Date                        
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12. APPENDIX G: ASSENT FORM FOR CHILD PARTICIPANT 
 
I, _____________________________________________ 
agree to be part of this study. The study has been explained to me and I understand the tests 
that will be performed on me. I have read or have had explained to myself, the information 
contained in the information sheet. 
 
 
__________________________                __________________            ___________ 
Name                                                           Signature/Thumbprint            Date 
 
 
__________________________                __________________            ___________ 
Doctors Name                                              Signature                                Date 
 
 
__________________________                __________________            ___________ 
Witness                                                         Signature/Thumbprint            Date 
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13. APPENDIX H: DATA CAPTURE SHEET 
 
Participant number: 
Date (dd/mm/yyyy):          Time:                   Date of birth (dd/mm/yyyy): 
Race: White      (Afrikaner Descent Y/N)   Indian       Black        Coloured            
Gender:   Female        Male 
Past medical history: Myocardial infarction      Angina       Heart failure      CVA     TIA 
Coronary artery bypass grafting     Coronary stent/ angioplasty     Carotid surgery  
Other vascular procedure/surgery:    Y/N 
If yes, list the procedure:_________________________ 
Treatment:   
Type of Medication 
Patients 
Treatment 
Dose of 
Medication 
Duration of 
Treatment 
(months) 
1. Statins 1 2 9   
2. Fibrates 1 2 9   
3. Bile acid 
sequestrant 
1 2 9 
  
4. Ezetimibe 1 2 9   
5. Niacin 1 2 9   
6. Other 
 
 
 
1 2 9 
  
1= Yes     2= No     9= Information is missing      
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Examination findings: 
Right eye  Left eye  
 Visual acuity 
Pinhole visual acuity 
 
Xanthelasma                   Y/N Eyelids Xanthelasma                     Y/N 
Xanthomata                     Y/N Conjunctiva Xanthomata                       Y/N 
Corneal arcus                    Y/N   If Yes 
Grade:       
 
Cornea 
Corneal Arcus                    Y/N    If Yes 
Grade: 
 Anterior chamber  
 Iris  
 Pupil  
Lens opacity  Y/N    If yes 1/2/3/4 
1= Cortical cataract 
2= Nuclear cataract 
3= Subcapsular cataract 
4= Other 
Lens 
Lens opacity   Y/N  If yes 1/2/3/4 
1= Cortical cataract 
2= Nuclear cataract 
3= Subcapsular cataract 
4= Other               
 Goldman applanation 
tonometry 
 
 Vitreous  
RVO       Y/N                If yes  
1= Branch retinal vein occlusion 
2= Central retinal vein occlusion  
RAO  Y/N                If yes 
1= Branch retinal artery occlusion 
2= Central retinal artery occlusion 
AMD      Y/N                 If yes   
1= Dry AMD 
2= Wet AMD 
 
Retinal arteriosclerosis    Y/N  If yes: 
Fundoscopy 
RVO        Y/N            If yes 
1=Branch retinal vein occlusion 
2= Central retinal vein occlusion 
RAO  Y/N                If yes 
1= Branch retinal artery occlusion 
2= Central retinal artery occlusion 
AMD        Y/N           If yes 
1= Dry AMD 
2= Wet AMD 
 
Retinal arteriosclerosis      Y/N If yes 
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1= Grade 1 
2= Grade 2 
3= Grade 3 
4= Grade 4 
 
Hollenhorst plaque      Y/N 
*Other findings: 
 
1= Grade 1 
2= Grade 2 
3= Grade 3 
4= Grade 4 
 
Hollenhorst plaque   Y/N 
*Other findings: 
 
 
Reliable               Y/N 
MD: 
PSD: 
CPSD:  
Visual field findings 
Reliable              Y/N 
MD: 
PSD: 
CPSD: 
 OCT findings  
MD= Mean deviation                                              PSD= Pattern standard deviation  
CPSD= Corrected pattern standard deviation 
Blood results: 
 
 
 
 
*Description of the disc and macula were documented under other findings.   
 
Total Cholesterol  
LDL  
HDL  
Triglycerides  
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14. APPENDIX I: PLAGIARISM FORM 
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15. APPENDIX J: TURNITIN ORIGINALITY REPORT 
 
 
